This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Melani, C. Articles by Colombo, M. P. Search for Related Content PubMed PubMed Citation Articles by Melani, C. Articles by Colombo, M. P.

Inhibition of Proliferation by c-myb Antisense Oligodeoxynucleotides in Colon Adenocarcinoma Cell Lines That Express c-myb¹

Division of Experimental Oncology D, Istituto Nazionale Tumori, Milan, Italy [C. M., L. R., G. P., M. P. C.], and Department of Pathology and Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia, Pennsylvania [B. C.]

Steady-state mRNA levels of the protooncogene c-myb were measured by Northern blot analysis in the human colon carcinoma cell lines LoVo, the doxorubicin-resistant derivative LoVo/Dx, Colo 205, and HT 29. Overexpression of c-myb mRNA was detected in the Colo 205 cell line, probably because of gene amplification, while in human HT 29 cells c-myb was not expressed at a detectable level. Comparison between LoVo and LoVo/Dx cell lines showed that c-myb mRNA levels were much higher in the doxorubicin-resistant derivative than in the parental line. c-myb antisense oligodeoxynucleotides inhibited cell proliferation only in the cell lines with detectable mRNA c-myb (LoVo, LoVo/DX, and Colo 205). The dose of antisense exerting inhibitory effect was related to the levels of c-myb mRNA expression. Inhibition of c-myb expression in antisense-treated LoVo/DX cells was demonstrated by the reverse transcriptase polymerase chain reaction technique.

LoVo/Dx cells were induced to differentiate by treatment with dimethylformamide to determine whether down-regulation of c-myb expression would accompany the process of differentiation. During the treatment with dimethylformamide the expression of c-myb decreased in parallel with the reduction of cell growth, while terminal differentiation of these cells was associated with changes in the expression of carcinoembryonic antigen and laminin receptor genes.

Our findings demonstrate that the expression of c-myb is important for the proliferation of colon carcinoma cell lines and suggest that the role of this protooncogene is not restricted to cells of hematopoietic origin but is more general than previously thought.

¹ This work was supported by Associazione Italiana per la Ricerca sul Cancro, Milan, Italy, by NIH Grant CA4678, and by American Cancer Society Grant CH-455. B. C. is a Scholar of the Leukemia Society of America.

² To whom requests for reprints should be addressed, at Department of Pathology, School of Medicine, Temple University, Broad and Ontario Streets, Philadelphia, PA 19140 [B.C.]; or Division of Experimental Oncology D, Instituto Nazionale Tumori, Milan, Italy [M.P.C.].

Received 8/28/90. Accepted 3/22/91.

This article has been cited by other articles:

				W. Lei, F. Liu, and S. A. Ness Positive and negative regulation of c-Myb by cyclin D1, cyclin-dependent kinases, and p27 Kip1 Blood, May 15, 2005; 105(10): 3855 - 3861. [Abstract] [Full Text] [PDF]

				A. Biroccio, B. Benassi, I. D'Agnano, C. D'Angelo, S. Buglioni, M. Mottolese, A. Ricciotti, G. Citro, M. Cosimelli, R. G. Ramsay, et al. c-Myb and Bcl-x Overexpression Predicts Poor Prognosis in Colorectal Cancer : Clinical and Experimental Findings Am. J. Pathol., April 1, 2001; 158(4): 1289 - 1299. [Abstract] [Full Text] [PDF]

				R. G. Ramsay, A. Friend, Y. Vizantios, R. Freeman, C. Sicurella, F. Hammett, J. Armes, and D. Venter Cyclooxygenase-2, a Colorectal Cancer Nonsteroidal Anti-inflammatory Drug Target, Is Regulated by c-MYB Cancer Res., April 1, 2000; 60(7): 1805 - 1809. [Abstract] [Full Text]

				I.-J. Moon, K. Choi, Y.-K. Choi, J.-E. Kim, Y. Lee, A. D. Schreiber, and J.-G. Park Potent Growth Inhibition of Leukemic Cells by Novel Ribbon-type Antisense Oligonucleotides to c-myb1 J. Biol. Chem., February 18, 2000; 275(7): 4647 - 4653. [Abstract] [Full Text] [PDF]

				M. Z. Ratajczak, D. Perrotti, P. Melotti, M. Powzaniuk, B. Calabretta, K. Onodera, D. A. Kregenow, B. Machalinski, and A. M. Gewirtz Myb and Ets Proteins Are Candidate Regulators of c-kit Expression in Human Hematopoietic Cells Blood, March 15, 1998; 91(6): 1934 - 1946. [Abstract] [Full Text] [PDF]

				T. C. Jarvis, F. E. Wincott, L. J. Alby, J. A. McSwiggen, L. Beigelman, J. Gustofson, A. DiRenzo, K. Levy, M. Arthur, J. Matulic-Adamic, et al. Optimizing the Cell Efficacy of Synthetic Ribozymes. SITE SELECTION AND CHEMICAL MODIFICATIONS OF RIBOZYMES TARGETING THE PROTO-ONCOGENE c-myb J. Biol. Chem., November 15, 1996; 271(46): 29107 - 29112. [Abstract] [Full Text] [PDF]

				K Sikora Current Issues in Cancer: Genes dreams and cancer BMJ, May 7, 1994; 308(6938): 1217 - 1221. [Full Text]